As we begin a new decade of research in trauma and orthopaedics, we should aim to make the most of the best available data. The last decade saw a huge increase in the volume of routinely recorded healthcare data. These datasets, particularly clinical registries and large administrative databases, can be valuable sources of information but need to be understood, analysed, interpreted, and reported carefully. We have previously highlighted the importance of understanding why a dataset was established, as well as the quality of the data in order to guide the interpretation of research findings. 1, 2 In this editorial, we aim to revisit both the importance of such data sources and the critical methodological principles that should be followed when drawing inferences from large datasets.
We recognise that big data offers the potential to answer many questions, particularly in relation to rare events and rare diseases, that cannot be answered using traditional methods. 3, 4 It also offers an opportunity to track practice over time and examine healthcare delivery throughout big healthcare systems. [5] [6] [7] [8] [9] [10] [11] [12] There is also huge potential in linking big data sets to address questions that cannot be looked at in any other ways. 5, 13 We have previously highlighted the dangers of misclassification bias, lumping, reliance on proxy outcomes, and overlooking both measured and unmeasured confounders. 1 We have also both celebrated and warned against the power of such large numbers; while alluring, they must be interpreted using sound clinical understanding. There is a risk that size of a datasets may expand at the expense of data quality, 14, 15 which needs to be carefully understood before inferences are drawn.
We should embrace the opportunities provided by large datasets, both to guide practice and generate hypotheses. However, although inferences drawn from registry data and administrative databases will increasingly contribute to debates, they cannot replace other study designs, particularly prospective cohort studies and randomised controlled trials. The appended framework for the reporting of registry and big data studies lays out the minimum information that should be presented, both to help readers interpret study findings appropriately and to improve the reproducibility of these important studies. Transparent reporting is at least as important in this arena as it is in others, and will be mandated.
Over the past few years, we have raised our expectations around study reporting and supported the use of well-established guidelines, such as the Consolidated Standards of Reporting Trials (CON-SORT), the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Strengthening and Reporting of Observational Studies in Epidemiology (STROBE) statements. We have previously suggested using the Reporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement for 'big data' studies. The information and guidelines recommended by Perry et al in 2014 were excellent and set a new standard that should be followed when reporting big data studies. 1 We suggested at the time that these should be used as an adjunct to the STROBE statement.
We now propose an expanded version that seeks to guide authors and to reassure readers. This document will further support methodological transparency and allow us to fully exploit the huge opportunities made available by large datasets. We also encourage authors to publish protocols for big data studies in our sister journal Bone & Joint Open, to reassure readers that any findings were not simply the result of statistical oddities from data mining, but were considered analyses based on a priori hypotheses. We do not believe that there is a conflict between our expanded recommendations and the RECORD statement, but welcome the views of our authors, readers, reviewers and other colleagues who work with big data or rely on such studies to inform their clinical practice. 
